User profiles for Gonzalo Carreño-Tarragona

Gonzalo Carreno-Tarragona

MD, PhD, Haematology and Haemotherapy Department, Hospital Universitario 12 de …
Verified email at salud.madrid.org
Cited by 1148

[HTML][HTML] Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels

…, K Dobbs, R Laguna-Goya, G Carreño-Tarragona… - MedRxiv, 2020 - ncbi.nlm.nih.gov
T cells are involved in the early identification and clearance of viral infections and also
support the development of antibodies by B cells. This central role for T cells makes them a …

[HTML][HTML] A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2

…, OM Delmonte, K Dobbs, G Carreño-Tarragona… - Research …, 2020 - ncbi.nlm.nih.gov
We describe the establishment and current content of the ImmuneCODE™ database, which
includes hundreds of millions of T-cell Receptor (TCR) sequences from over 1,400 subjects …

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

…, L Fernández, G Carreño-Tarragona… - Blood Cancer …, 2021 - nature.com
CAR-T-cell therapy against MM currently shows promising results, but usually with serious
toxicities. CAR-NK cells may exert less toxicity when redirected against resistant myeloma …

Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies

…, C Cuellar, G CarreñoTarragona… - European Journal of …, 2020 - Wiley Online Library
Background The impact of coronavirus disease 2019 (COVID‐19) in haematological patients
(HP) has not been comprehensively reported. Methods We analysed 39 patients with SARS…

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

…, KSQ Cervantes, MS Serrano, G Carreno-Tarragona… - Leukemia, 2021 - nature.com
We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. …

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

…, Y Hoade, WJ Tapper, G Carreno-Tarragona… - Leukemia, 2019 - nature.com
Determining the underlying cause of persistent eosinophilia is important for effective clinical
management but remains a diagnostic challenge in many cases. We identified STAT5B …

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

G Carreño-Tarragona, A Álvarez-Larrán… - Blood …, 2023 - ashpublications.org
Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare
myeloid disorders that are challenging with regard to diagnosis and clinical management. …

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance …

…, B Xicoy, MJ Ramírez, G CarreñoTarragona… - Cancer, 2022 - Wiley Online Library
Background Ruxolitinib is approved for patients with polycythemia vera (PV) who are
resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression …

[HTML][HTML] Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission …

…, I Rapado, ML Morales, G Carreño-Tarragona… - …, 2021 - ncbi.nlm.nih.gov
In cases of treatment failure in acute myeloid leukemia (AML), the utility of mutational profiling
in primary refractoriness and relapse is not established. We undertook a perspective study …

Optical nanoparticles for cardiovascular imaging

…, N Fernandez, G CarreñoTarragona… - Advanced Optical …, 2018 - Wiley Online Library
The current status of the use of optical nanoparticles for imaging of the cardiovascular
system is reviewed in detail. The different types of optical (luminescent, photoacoustic, and …